First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Erythromelalgia
AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing targeted, first-in-class therapeutics for peripheral neuropathic pain, announces it has dosed the…